Print

Rituximab Ups Survival in Chronic Lymphocytic Leukemia (CLL), University of Cologne Study  
10/1/2010 6:22:15 AM

MedPageToday -- Adding the monoclonal antibody rituximab (Rituxan) to initial chemotherapy significantly improved progression-free and overall survival in patients with chronic lymphocytic leukemia (CLL), a prospective study found.
//-->